Results for tag: "Capmatinib"

Capmatinib is an oncology drug used to treat non-small cell lung cancer (NSCLC). It is a type of tyrosine kinase inhibitor (TKI) that works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. It is approved for use in patients with metastatic NSCLC whose tumors have a mutation in the MET gene. Capmatinib is administered orally and is available in tablet form. Capmatinib is a relatively new drug and is still in the early stages of development. It has been studied in clinical trials and has shown promise in treating NSCLC. It is currently being evaluated in combination with other drugs for the treatment of NSCLC. Capmatinib is marketed by Novartis, AstraZeneca, and Boehringer Ingelheim. It is also being developed by several other companies, including Merck, Pfizer, and Eli Lilly. Show Less Read more